by admin | Nov 25, 2019 | FDA
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigational survival motor neuron-2 (SMN-2) splicing modifier for spinal...
by admin | Nov 25, 2019 | Clinical Trials
Celularity, a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer...
by admin | Nov 25, 2019 | M&A - Buy-Out
The Medicines Company announced that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash transaction, implying a fully diluted equity value of $9.7 billion. The price represents a premium of...
by admin | Nov 25, 2019 | FDA
Usona Institute has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for psilocybin in the treatmentof major depressive disorder (MDD). Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an...
by admin | Nov 25, 2019 | Funding
Azeria Therapeutics, a newly formed pioneer factor drug discovery company, announced a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor the CRT Pioneer Fund. Azeria was originally founded in 2017 by Sixth Element...
